[6-K] GSK plc Current Report (Foreign Issuer)
GSK plc reported share repurchases under its ongoing buyback programme. On 18 September 2025 the Company, through Merrill Lynch International, purchased 15,858 ordinary shares at prices between 1,471.00p and 1,480.00p, with an aggregated per-share reference of 1,476.54p. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 29,330,461 ordinary shares. After these transactions GSK holds 247,464,844 shares in treasury and has 4,067,938,124 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,067,938,124 and the percentage of voting rights attributable to treasury shares is stated as 6.08%.
GSK plc ha riportato riacquisti azionari nell'ambito del suo programma di riacquisto in corso. Il 18 settembre 2025 la Società, tramite Merrill Lynch International, ha acquistato 15.858 azioni ordinarie a prezzi tra 1.471,00p e 1.480,00p, con un riferimento per azione aggregato di 1.476,54p. Da quando è iniziato l'accordo non discrezionale il 4 giugno 2025 la Società ha acquistato 29.330.461 azioni ordinarie. Dopo queste operazioni GSK detiene 247.464.844 azioni in tesoreria e ha in circolazione 4.067.938.124 azioni ordinarie (escludendo le azioni in tesoreria). Il numero totale di diritti di voto è 4.067.938.124 e la percentuale dei diritti di voto attribuibile alle azioni in tesoreria è indicata come 6,08%.
GSK plc informó sobre recompras de acciones dentro de su programa de recompra en curso. El 18 de septiembre de 2025, la Compañía, a través de Merrill Lynch International, compró 15.858 acciones ordinarias a precios entre 1.471,00p y 1.480,00p, con una referencia por acción agregada de 1.476,54p. Desde que comenzó el acuerdo no discrecional el 4 de junio de 2025, la Compañía ha adquirido 29.330.461 acciones ordinarias. Tras estas operaciones GSK posee 247.464.844 acciones en tesorería y tiene 4.067.938.124 acciones ordinarias en circulación (excluyendo tesorería). El total de derechos de voto es 4.067.938.124 y el porcentaje de derechos de voto atribuido a las acciones en tesorería se indica como 6,08%.
GSK plc는 진행 중인 자사주 매입 프로그램에 따른 주식 매입을 보고했습니다. 2025년 9월 18일 회사는 Merrill Lynch International를 통해 15,858주의 보통주를 1,471.00p에서 1,480.00p 사이의 가격으로 매입했으며, 주당 기준 총합은 1,476.54p로 확인됩니다. 2025년 6월 4일 비재량적 합의가 시작된 이후 회사는 29,330,461주의 보통주를 매입했습니다. 이러한 거래 이후 GSK는 247,464,844주의 보유고를 보유하고 있으며 발행주식은 4,067,938,124주(재고 제외)입니다. 의결권 총수는 4,067,938,124주이며 재고주식에 귀속하는 의결권 비율은 6.08%로 표시됩니다.
GSK plc a annoncé des rachats d’actions dans le cadre de son programme de rachat en cours. Le 18 septembre 2025, la société, par l’intermédiaire de Merrill Lynch International, a acheté 15 858 actions ordinaires à des prix compris entre 1 471,00p et 1 480,00p, avec une référence par action agrégée de 1 476,54p. Depuis le début de l’accord non discrétionnaire le 4 juin 2025, la société a acheté 29 330 461 actions ordinaires. Après ces transactions, GSK détient 247 464 844 actions en trésorerie et a en circulation 4 067 938 124 actions ordinaires (hors trésorerie). Le nombre total de droits de vote est 4 067 938 124 et le pourcentage des droits de vote attribuable aux actions en trésorerie est indiqué comme 6,08%.
GSK plc meldete Rückkäufe von Aktien im Rahmen seines laufenden Rückkaufprogramms. Am 18. September 2025 kaufte das Unternehmen über Merrill Lynch International 15.858 Stammaktien zu Preisen zwischen 1.471,00p und 1.480,00p, mit einer aggregierten Referenz pro Aktie von 1.476,54p. Seit dem Beginn der nichtdiskretionären Vereinbarung am 4. Juni 2025 hat das Unternehmen 29.330.461 Stammaktien erworben. Nach diesen Transaktionen hält GSK 247.464.844 Aktien in Treasuries und hat 4.067.938.124 ausstehende Stammaktien (ohne Treasury). Die Gesamtanzahl der Stimmrechte beträgt 4.067.938.124 und der Anteil der Stimmrechte, der den Treasury-Aktien zuzurechnen ist, wird mit 6,08% angegeben.
أعلنت شركة GSK عن إعادة شراء الأسهم ضمن برنامجها المستمر لإعادة الشراء. في 18 سبتمبر 2025، وبواسطة Merrill Lynch International، اشترت 15,858 سهماً عريضاً بأسعار بين 1,471.00p و 1,480.00p، مع مرجع إجمالي للسهم الواحد قدره 1,476.54p. منذ بدء الاتفاق غير التقديري في 4 يونيو 2025، اشترت الشركة 29,330,461 سهماً عريضاً. بعد هذه المعاملات تمتلك GSK 247,464,844 أسهماً خزينة وتصدر 4,067,938,124 أسهماً عادية قائمة (باستثناء الخزينة). العدد الإجمالي لحقوق التصويت هو 4,067,938,124 ونسبة حقوق التصويت المنسوبة إلى أسهم الخزينة موضحة بأنها 6.08%.
GSK plc 报告了在其进行中的回购计划下的股票回购。 2025年9月18日，公司通过美林国际(Merrill Lynch International)以介于 1,471.00p 与 1,480.00p 的价格购买了 15,858 股普通股，单股平均参考价格为 1,476.54p。自2025年6月4日非自由裁量协议开始以来，公司已回购 29,330,461 股普通股。经此等交易后，GSK 持有 247,464,844 股库藏股，已发行普通股数量为 4,067,938,124 股（不含库藏股）。总股本的表决权为 4,067,938,124 股，归属库藏股的表决权比例标示为 6.08%。
- Transparent, trade-level disclosure of individual transactions and trading venues supports investor clarity
- Cumulative repurchases of 29,330,461 shares since 4 June 2025 demonstrate active execution of the buyback programme
- Voting-rights denominator provided (4,067,938,124) and treasury percentage (6.08%) enable shareholder threshold calculations
- Today's volume is very small (15,858 shares) and is immaterial versus shares outstanding, so limited immediate market impact
- No information on total programme size or remaining authority is provided in this notice
Insights
TL;DR: Continued, routine buybacks; cumulative purchases since June notable but today's volume is immaterial to share count.
The disclosed transaction shows GSK executing its announced non-discretionary buyback via its broker across UK trading venues. The company reports precise trade-level pricing and confirms cumulative purchases of 29,330,461 shares since 4 June 2025, with 247,464,844 held in treasury and voting-rights impact of 6.08%. The day's volume of 15,858 shares is negligible relative to total shares outstanding of 4,067,938,124, indicating routine execution rather than a material market operation.
TL;DR: Disclosure is compliant and granular, showing adherence to DTR reporting requirements.
GSK provides full transaction-level detail and confirms the voting-rights denominator, enabling shareholders to assess notification thresholds. The statement includes the required percentage figure for treasury-held voting rights (6.08%) and identifies the broker and trading venues, supporting transparency in the buyback programme's implementation.
GSK plc ha riportato riacquisti azionari nell'ambito del suo programma di riacquisto in corso. Il 18 settembre 2025 la Società, tramite Merrill Lynch International, ha acquistato 15.858 azioni ordinarie a prezzi tra 1.471,00p e 1.480,00p, con un riferimento per azione aggregato di 1.476,54p. Da quando è iniziato l'accordo non discrezionale il 4 giugno 2025 la Società ha acquistato 29.330.461 azioni ordinarie. Dopo queste operazioni GSK detiene 247.464.844 azioni in tesoreria e ha in circolazione 4.067.938.124 azioni ordinarie (escludendo le azioni in tesoreria). Il numero totale di diritti di voto è 4.067.938.124 e la percentuale dei diritti di voto attribuibile alle azioni in tesoreria è indicata come 6,08%.
GSK plc informó sobre recompras de acciones dentro de su programa de recompra en curso. El 18 de septiembre de 2025, la Compañía, a través de Merrill Lynch International, compró 15.858 acciones ordinarias a precios entre 1.471,00p y 1.480,00p, con una referencia por acción agregada de 1.476,54p. Desde que comenzó el acuerdo no discrecional el 4 de junio de 2025, la Compañía ha adquirido 29.330.461 acciones ordinarias. Tras estas operaciones GSK posee 247.464.844 acciones en tesorería y tiene 4.067.938.124 acciones ordinarias en circulación (excluyendo tesorería). El total de derechos de voto es 4.067.938.124 y el porcentaje de derechos de voto atribuido a las acciones en tesorería se indica como 6,08%.
GSK plc는 진행 중인 자사주 매입 프로그램에 따른 주식 매입을 보고했습니다. 2025년 9월 18일 회사는 Merrill Lynch International를 통해 15,858주의 보통주를 1,471.00p에서 1,480.00p 사이의 가격으로 매입했으며, 주당 기준 총합은 1,476.54p로 확인됩니다. 2025년 6월 4일 비재량적 합의가 시작된 이후 회사는 29,330,461주의 보통주를 매입했습니다. 이러한 거래 이후 GSK는 247,464,844주의 보유고를 보유하고 있으며 발행주식은 4,067,938,124주(재고 제외)입니다. 의결권 총수는 4,067,938,124주이며 재고주식에 귀속하는 의결권 비율은 6.08%로 표시됩니다.
GSK plc a annoncé des rachats d’actions dans le cadre de son programme de rachat en cours. Le 18 septembre 2025, la société, par l’intermédiaire de Merrill Lynch International, a acheté 15 858 actions ordinaires à des prix compris entre 1 471,00p et 1 480,00p, avec une référence par action agrégée de 1 476,54p. Depuis le début de l’accord non discrétionnaire le 4 juin 2025, la société a acheté 29 330 461 actions ordinaires. Après ces transactions, GSK détient 247 464 844 actions en trésorerie et a en circulation 4 067 938 124 actions ordinaires (hors trésorerie). Le nombre total de droits de vote est 4 067 938 124 et le pourcentage des droits de vote attribuable aux actions en trésorerie est indiqué comme 6,08%.
GSK plc meldete Rückkäufe von Aktien im Rahmen seines laufenden Rückkaufprogramms. Am 18. September 2025 kaufte das Unternehmen über Merrill Lynch International 15.858 Stammaktien zu Preisen zwischen 1.471,00p und 1.480,00p, mit einer aggregierten Referenz pro Aktie von 1.476,54p. Seit dem Beginn der nichtdiskretionären Vereinbarung am 4. Juni 2025 hat das Unternehmen 29.330.461 Stammaktien erworben. Nach diesen Transaktionen hält GSK 247.464.844 Aktien in Treasuries und hat 4.067.938.124 ausstehende Stammaktien (ohne Treasury). Die Gesamtanzahl der Stimmrechte beträgt 4.067.938.124 und der Anteil der Stimmrechte, der den Treasury-Aktien zuzurechnen ist, wird mit 6,08% angegeben.
FAQ
How many shares did GSK (GSK) buy on 18 September 2025?
What price range did GSK pay for shares on 18 September 2025?
How many shares has GSK repurchased since 4 June 2025?
How many shares does GSK hold in treasury after this purchase?
What is the total number of GSK voting rights after the purchase?
